SCHEMBL20098035

SCHEMBL20098035

CC1(Nc2nc3ccccc3s2)N=C(c2ccccc2)c2ccccc2NC1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK10 O94804 1/20 0.39
SLK Q9H2G2 1/20 0.39
NPC1 O15118 5/20 0.39
RAB9A P51151 5/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
RXFP1 Q9HBX9 1/20 0.39
SCD O00767 1/20 0.39
ADORA1 P30542 1/20 0.38
DYRK1A Q13627 1/20 0.38
MAPT P10636 5/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
ALDH1A1 P00352 3/20 0.38
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
ADORA2A P29274 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRG2 P18507 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20098036 0.78 ALDH1A1 (0.41) NPC1RAB9ASMN1; SMN2ALDH1A1ADORA2A
SCHEMBL21117035 0.77 CCKAR (0.38) MEN1KMT2AMAPTALDH1A1GABRA1
SCHEMBL20098037 0.77 NPC1 (0.40) NPC1RAB9AMEN1KMT2ADYRK1A
SCHEMBL20098137 0.73 CCKBR (0.52)
SCHEMBL20098666 0.72 GABRA1 (0.39) MEN1KMT2AMAPTALDH1A1GABRA1
SCHEMBL5803308 0.71 GABRA1 (0.53) MEN1KMT2AMAPTALDH1A1GABRA1
SCHEMBL21755152 0.69 GABRA1 (0.50) MEN1KMT2AMAPTALDH1A1GABRA1
SCHEMBL22022340 0.69 GABRA1 (0.50) MEN1KMT2AMAPTALDH1A1GABRA1
SCHEMBL21755197 0.67 ADCY1 (0.43) MEN1KMT2ASMN1; SMN2ALDH1A1POLB
SCHEMBL20098184 0.67 ADCY1 (0.43) MEN1KMT2ASMN1; SMN2ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10881666-B2 Combination pharmaceutical agents as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2021-01-05 US disclosed
US-10865215-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2020-12-15 US disclosed
US-20200223867-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARM INC (US) 2020-07-16 US disclosed
US-10570153-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2020-02-25 US disclosed
US-20190192535-A1 COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2019-06-27 US disclosed
US-9957281-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2018-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10865215-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 STK10 2246/4885SLK 1643/4885NPC1 224/4885
US-10881666-B2 Combination pharmaceutical agents as RSV inhibitors SERPINB1, FURIN, HIF1AN STK10 972/4885SLK 2134/4885NPC1 480/4885
US-10570153-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 STK10 2246/4885SLK 1643/4885NPC1 224/4885
US-20200223867-A1 BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS GABRA5, GABRA1, GABBR2 STK10 2246/4885SLK 1643/4885NPC1 224/4885
US-20190192535-A1 COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS SERPINB1, FURIN, HIF1AN STK10 972/4885SLK 2134/4885NPC1 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.